Last month, SafePulse presented to the All-Party Parliamentary Group on Drug Policy Reform. The session focused on image-enhancing drug use in the UK — where the evidence sits, where the gaps are, and what a harm-reduction framework could practically look like at a policy level.
The appetite in the room for an evidence-first conversation was higher than we expected. There was broad agreement that the current position — a de-facto silence from clinical services, paired with a near-total absence of policy — is not serving users, families, or the wider health system. The disagreements were about pace and mechanism, not direction.
We left with three asks on the table: a commissioned review of the harm-reduction evidence base, a costed pilot clinical pathway for a small cohort of practices, and a public consultation on NHS guidance for performance-enhancing drug users. None of that will move quickly, but the door is now open.